The drug did, however, significantly improve progression-free survival.
Though they are costly, broad genetic assays that look for many gene mutations at once may confer more value overall than a one-off testing approach for patients with nsNSCLC.
Overall, grade 3 to 4 AEs were noted in 33% of patients receiving the immunotherapy combination vs 36% of patients receiving chemotherapy.
In the 3 ongoing responses, all had PD-L1–positive disease.
Three of 9 patients with measurable central nervous system metastases had an intracranial complete response, with a 56% overall response rate in this subgroup.
Twenty-six (61.9%) patients had an ORR as confirmed by independent central review.